Printer Friendly

SIGA Pharmaceuticals Receives Research Grants.

NEW YORK--(BUSINESS WIRE)--Oct. 6, 1999--

SIGA Pharmaceuticals, Inc. (NASDAQ: SGPH) announced today that it has been awarded two research grants totaling $400,000. The grants will support antibiotic and strep throat vaccine development programs at SIGA Research Labs, the Company's research and development facility. The grants were awarded by the Small Business Innovation Research Program (SBIR) of the National Institutes of Health.

The first grant will support the Company's antibiotic discovery efforts. SIGA's antibiotics programs are aimed at "disarming" bacteria by interfering with the expression of bacterial surface proteins. Surface proteins are used by bacteria in the attachment to human tissue, the first step in the infection process. No existing antibiotics act through this mechanism.

The second grant will support the development of a subunit vaccine targeting strep throat based on the Company's proprietary antigen. Strep throat can be caused by more than 120 different types of group A streptococcus, and SIGA's technology is based on a region of the streptococcus M protein that is common to the multiple types of the disease causing bacteria. SIGA is currently developing StrepImmune, a group A streptococcal vaccine candidate based on the Company's proprietary commensal bacteria delivery system. The StrepImmune program is being developed through a collaboration with the National Institutes of Health. "The development of a subunit vaccine will complement our existing vaccine efforts and will provide us with a second vaccine candidate for commercial development," said Dennis Hruby, Ph.D., SIGA's Vice President for Research.

Group A streptococcal pharyngitis, or strep throat, is one of the most common childhood diseases, affecting approximately 10 million children in the United States each year and a comparable number in Europe. Ineffectively treated, this disease, for which there is no vaccine available, can progress to rheumatic fever, ultimately leading to cardiac damage.

"These grants are an important endorsement of the quality of the underlying science at SIGA Research Labs," said Joshua D. Schein, Ph.D, SIGA's Chief Executive Officer. "Importantly, these awards will assist the Company in its objective of making its biotechnology operations self-sufficient as we continue to explore alternative strategies to maximize shareholder value," he added.

This news release contains forward-looking statements that involve risk and uncertainties. The development of SIGA's products may differ materially from the Company's expectations. Among the factors that could result in a materially different outcome are the inherent uncertainties accompanying drug discovery, clinical trials and new product development.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Oct 6, 1999
Previous Article:OASIS Grows as Concern for XML Interoperability Rises; Corel, Extricity Software, Keyfile and XMLSolutions Join International XML Consortium.
Next Article:The Internet Analyst News - France and Benelux: A New Market for New Companies.

Related Articles
Siga Achieves First Milestone in Military Defense Research Program.
SIGA Pharmaceuticals Announces U.S. Patent for Strep Throat Vaccine Technology.
SIGA Pharmaceuticals Announces Strategic Initiative.
SIGA Achieves Second Milestone in Military Defense Research Program.
SIGA Technologies Receives $865,000 Phase II Research Grant for Antibiotic Development.
Genomatica awarded $765,000 Phase II SBIR grant from NIH.
Diabetes nurses win research funding.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters